COMMUNIQUÉS West-GlobeNewswire

AC Immune Announces Retirement of CEO Dr Andrea Pfeifer at Upcoming AGM
12/05/2026
AC Immune Announces Retirement of CEO Dr Andrea Pfeifer at Upcoming AGM Co-founder and CEO, Dr Andrea Pfeifer, to retire after a distinguished 23-year tenure Board Chair, Martin Zügel, MD, to be appointed interim CEO Dr [...]
Immatics Announces First Quarter 2026 Financial Results and Business Update
12/05/2026
SUPRAME Phase 3 interim and final analysis for PRAME cell therapy, anzu-cel, expected to be triggered in 2026, advancing toward the Company’s first commercial launch planned in 2027 Multiple key clinical data sets [...]
Foghorn Therapeutics to Participate in Three Upcoming Investor Conferences in May
12/05/2026
WATERTOWN, Mass., May 12, 2026 (GLOBE NEWSWIRE) -- Foghorn ® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting [...]
Arbor Biotechnologies Achieves Unprecedented Precise In Vivo Reverse Transcriptase Editing in the Brain Using a Single AAV Vector, Opening a New Path to Treatments for Neurological Diseases
12/05/2026
- Oral presentation at ASGCT showcases breakthrough technology enabling precise in vivo genome editing in the CNS using a single AAV vector - Two poster presentations describe methods that support accelerated [...]
Ovid Therapeutics Reports Business Updates and First Quarter 2026 Financial Results
12/05/2026
Dosed first participant with OV4071, the first-ever oral potassium-chloride cotransporter 2 (KCC2) direct activator, in May 2026 in a Phase 1 study with healthy volunteers OV329 showed favorable safety, tolerability, [...]
Tenax Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
12/05/2026
On track to report topline data from Phase 3 LEVEL study of TNX-103 in third quarter of 2026 Global Phase 3 LEVEL-2 clinical trial ongoing, enrollment completion anticipated by end of 2027 Strengthened leadership team [...]
Arvinas and Pfizer Enter into a Transaction with Rigel Pharmaceuticals for the Exclusive Global Rights of VEPPANU (vepdegestrant)
12/05/2026
– Arvinas and Pfizer to receive $85 million in upfront and transition payments with potential for additional $320 million in development, regulatory, and commercial milestones and tiered royalites on net sales – NEW [...]
Medicenna and Fondazione Melanoma Onlus Announce First Patient Dosed in the NEO-CYT Study of MDNA11 in Neoadjuvant Melanoma
12/05/2026
NEO-CYT marks the first evaluation of MDNA11 in earlier-stage cancers, as a potentially curative treatment; extends development beyond the heavily pretreated metastatic setting of the ongoing Phase 1/2 ABILITY-1 study [...]
Enterome presents Phase 2 indolent non-Hodgkin lymphoma data at EHA showing EO2463 induces B cell target-specific CD8 T-cell expansion correlating with clinical outcomes
12/05/2026
Interim results from SIDNEY Phase 2 trial show EO2463 rapidly induced extensive in vivo expansion of B cell target-specific CD8 T-cells Correlation established between EO2463-induced and B cell target-specific CD8 T- [...]
Transactions in connection with share buy-back program
12/05/2026
Company announcement no. 16 - 26 12 May 2026 Transactions in connection with share buy-back program On 4 March 2026 NTG Nordic Transport Group (“NTG”) announced a share buy-back program, as described in company [...]
ViCentra Announces Commercial Launch of New Smartphone-Controlled Kaleido Automated Insulin Delivery Patch Pump System
12/05/2026
New system combines Kaleido with Diabeloop’s DBLG2 algorithm and Dexcom G7, with first commercial deliveries in Germany and the Netherlands planned for later this summer Enables insulin automation to be controlled [...]
AstronauTx builds executive team with appointment of experienced clinical development leader Michelle Mellion, MD as Chief Medical Officer
12/05/2026
Brings more than 20 years of neurology, clinical development, and translational experience as AstronauTx prepares to advance its lead programmes into clinical development AstronauTx also appoints Deb Gouveia as Vice [...]
Orion Animal Health receives US FDA approval for Tessie® (tasipimidine oral solution) for the treatment of noise aversion and separation anxiety in dogs
12/05/2026
ORION CORPORATION PRESS RELEASE 12 MAY 2026 at 10:30 EEST Orion Animal Health receives US FDA approval for Tessie® (tasipimidine oral solution) for the treatment of noise aversion and separation anxiety in dogs Orion [...]
Infex Therapeutics secures £4.3 million funding to advance anti-infective pipeline targeting drug-resistant infections
12/05/2026
Investment led by Jon Moulton supports progression of clinical and preclinical programmes addressing critical-priority pathogens Infex to present results from Phase IIa trial for first-in-class anti-virulence therapy [...]
Coloplast A/S - Announcement no. 05/2026 - Interim Financial Report, H1 2025/26
12/05/2026
2025/26 Interim financial results, H1 2025/26 1 October 2025 - 31 March 2026 Coloplast delivered Q2 organic growth of 6% and 6% EBIT growth 1 in constant currencies. Strong quarter in Chronic Care and Interventional [...]
Novo Nordisk A/S: Higher dose Wegovy® demonstrates nearly 28% weight loss in early responders according to new analyses presented at the European Congress on Obesity
12/05/2026
Early responders (15% or more weight loss after 24 weeks) to the higher dose of Wegovy ® (semaglutide 7.2 mg) achieved on average 27.7% mean weight loss at week 72 in the STEP UP trial 1 Participants treated with the [...]
Roche receives CE mark for new blood test to detect Alzheimer's pathology: Elecsys® plasma phosphorylated-tau 217 (pTau217)
12/05/2026
Elecsys® pTau217 is the first blood test for Alzheimer’s disease pathology with a single ‑ assay design, intended to rule in and rule out amyloid pathology across primary and secondary care, offering faster diagnosis [...]
BioPorto A/S to host an investor webcast on the results for the first quarter of 2026
12/05/2026
May 12, 2026 News release BioPorto A/S to h ost an investor webcast on the results for the first quarter of 202 6 COPENHAGEN, DENMARK, May 12, 2026 (GLOBE NEWSWIRE) – BioPorto A/S (BioPorto or the Company) (CPH:BIOPOR [...]
Coloplast A/S - Announcement no. 05/2026 - Interim Financial Report, H1 2025/26
12/05/2026
2025/26 Interim financial results, H1 2025/26 1 October 2025 - 31 March 2026 Coloplast delivered Q2 organic growth of 6% and 6% EBIT growth 1 in constant currencies. Strong quarter in Chronic Care and Interventional [...]

Pages